IDEAYA Biosciences Inc. (NASDAQ: IDYA) announced it has completed enrollment of 435 patients in its pivotal Phase 2/3 trial evaluating ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE